Responsible for leading all business and partnering activities at ArtiosEastablished the US presence of Artios in 2019Recent, pivotal for the business, transactions: 1) Sourced, led, negotiated and managed all stages of the Novartis and Artios collaboration to create next generation DDR cancer therapies, announced April 7, 2021; US$20 million up-front payment in addition to research funding, and eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones, in addition to royalty payments.2) Sourced, led, negotiated and managed all stages of the Merck KGaA and Artios’ global strategic collaboration to develop novel DNA damage response targets in oncology, announced December 3, 2020; US$30 million in up-front payment, R&D financing, double-digit option fees and eligible to receive up to US$6.9 billion in total milestones for up to 8 targets, in addition to royalties on product net sales.3) Led, negotiated and managed all stages of the in-licensing of the small molecule ATR inhibitor program developed by The University of Texas MD Anderson Cancer Center and ShangPharma Innovation by Artios, announced November 6, 2019

Leads and executes the initiation, progression and negotiation of M&A, licensing, partnership and investment transactionsBuilds and manages collaborative relationships across the organization to create internal alignment and develop partnersEngages and coordinates cross-functional teams to evaluate opportunities, scope, structure and implement new relationshipsDevelops and implements global BD strategies in collaboration with regional strategy, technical, legal and commercial leads, such as screening activities to identify and prioritize investing, partnership and M&A opportunitiesSources, prioritizes, structures and executes Immuno-Oncology (IO) combination trial agreements with outside partners on anti-PD-L1 (avelumab); Leads monthly internal and external meetings, with partner Merck KGaA, on deal review and prioritization Generates and delivers BD and Strategy presentations to internal and external audiences to develop partners; Worked on special, high priority projects for Global Divisional President and the Office of the Chief Executive OfficerFosters engagement with the biopharma community by leveraging large internal and external network − Represents Pfizer at multiple partnering events and ensures thorough review of opportunities inside and outside BD− Mentors local start-ups preparing for investor pitches, Panelist and corporate presenter at healthcare forums− Led organization-wide effort to change partnership culture and perception about Pfizer’s effective partnering abilities Recent transactions: 1) Global development and commercialization alliance with Merck KGaA on anti-PD-L1 to accelerate Pfizer’s presence in immuno-oncology ($850M upfront and ~ $2B in potential regulatory and commercial milestones), 2) Acquisition of Nimenrix and Mencevax, quadrivalent meningitis ACWY vaccines, for ~ $130M from GSK, 3) Acquisition of Redvax GmbH, Swiss venture backed startup, to gain access to a preclinical human CMV vaccine candidate

Managed and coordinated all stages of the origination, due diligence and execution of M&A/ divestiture activitiesResponsible for connecting with venture capitalist funds, incubators, healthcare start-up communities, and industry experts to search for investing opportunities, while providing qualitative insights for strategic transactionsAnalyzed therapeutic and disease area landscape, and conducted deep dives into company financials, programs and products Updated management team on biotechnology landscape evolution and external pressures that can impact company strategyAssessed potential risk/reward profiles for various assets and opportunity sizing in order to make rapid, informed decisions Selected to receive Bristol-Myers Squibb Galaxy Award for Leadership for the 2013 $115M sale of RecothromTransactions : Acquisition of iPierian ($550M), divestitures of Recothrom ($115M) and Latin American brands ($452M)

Suffolk Capital is a long-only, diversified U.S. equitities investment boutique with a 20-year track recordSolely responsible for generating new investment ideas and maintaining coverage across the entire spectrum of healthcare – biotechnology, pharma, medical devices, health insurers, services and IT – for a $1.5B portfolioAssisted a senior generalist PM with the healthcare investment decisions during daily idea generation meetings

BD Diagnostics, Global Marketing - Preanalytical Systems

Analyzed and developed investment recommendations for 40 large and mid-cap global health care companies in major, specialty and generic pharmaceuticals, biotechnology, medical device and health care services sectors. Led a team of three international health care analysts, two in Zurich and one in Singapore, and managed flow of health care-related investment ideas and products within Global Equity Research Department.Wrote investment idea and research reports which identify long-term global health care investment themes, including global pharma/biotech M&A and alliances trends, and competitive landscape.Developed weekly long-only and long/short health care trades based on primary research and investment analysis process.Initiated coverage of emerging markets health care companies in Eastern Europe and Asia. Co- organized and participated in the execution of an interactive investor visit to Bulgaria for CS’s top 25 high net worth clients, and the creation of investment products related to that area. Interviewed senior management teams of companies under coverage, and developed a network of healthcare thought leaders.

Performed company and sector analysis in support of Institutional Investor ranked senior analyst in large cap pharma, specialty & generic pharmaceuticals Built company models and wrote company specific and industry wide reports; models included revenue builds, market penetration analyses based on prescription/patient data, and detailed equity valuation modelsConducted due diligence of private healthcare companies as they pursued the public marketsCommunicated investment ideas to internal sales force, sector traders and clients Produced semi-annual U.S. Healthcare Strategy, quarterly Earnings Previews and weekly Catalyst Insights reports covering all healthcare sectors